Timna Agur

Timna Agur

Auto-generated profile, based on publicly available information

Timna Agur

Department of Nephrology and Hypertension, Rabin Medical Center, Petah Tikva, Israel

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2021 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
TATimna Agur
Timna Agur
NBNaomi Ben-Dor
Naomi Ben-Dor
SGShira Goldman
Shira Goldman
SLShelly Lichtenberg
Shelly Lichtenberg
MHMichal Herman-Edelstein
Michal Herman-Edelstein
BZBoris Zingerman
Boris Zingerman
Timna Agur, Naomi Ben-Dor, Shira Goldman, Shelly Lichtenberg, Michal Herman-Edelstein, Dafna Yahav, Benaya Rozen-Zvi, Boris Zingerman; Antibody response to mRNA

Verified
Journal Article
Open access
PDF file
OKOlga Lesya Kukuy
Olga Lesya Kukuy
RCRon Cohen
Ron Cohen
BGBoris Gilburd
Boris Gilburd
EZEleanor Zeruya
Eleanor Zeruya
TWTalia Weinstein
Talia Weinstein
OSOra Shovman
Ora Shovman
Anti-PLA2R antibodies (Ab) are a diagnostic and prognostic biomarker in primary membranous nephropathy (PMN). We assessed the relationship between the levels of anti-PLA2R Ab at diagnosis and different variables related to disease activity and prognosis in a western population of PMN patients. Forty-one patients with positive anti-PLA2R Ab from three nephrology departments in Israel were enrolled. Clinical and laboratory data were collected at diagnosis and after one year of follow-up, including serum anti-PLA2R Ab levels (ELISA) and glomerular PLA2R deposits on biopsy. Univariable statistical analysis and permutation-based ANOVA and ANCOVA tests were performed. The median [(interquartile range (IQR)) age of the patients was 63 [50–71], with 28 (68%) males. At the time of diagnosis, 38 (93%) of the patients had nephrotic range proteinuria, and 19 (46%) had heavy proteinuria (≥8 gr/24 h). The median [IQR] level of anti-PLA2R at diagnosis was 78 [35–183] RU/mL. Anti-PLA2R levels at diagnosis were correlated with 24 h proteinuria, hypoalbuminemia and remission after one year (p = 0.017, p = 0.003 and p = 0.034, respectively). The correlations for 24 h proteinuria and hypoalbuminemia remained significant after adjustment for immunosuppressive treatment (p = 0.003 and p = 0.034, respectively). Higher levels of anti-PLA2R Ab at diagnosis in patients with active PMN from a western population are associated with higher proteinuria, lower serum albumin and remission one year after the diagnosis. This finding supports the prognostic value of anti-PLA2R Ab levels and their possible use in stratifying PMN patients.

28 February 2025 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
TATimna Agur
Timna Agur
TSTali Steinmetz
Tali Steinmetz
SGShira Goldman
Shira Goldman
BZBoris Zingerman
Boris Zingerman
DBDana Bielopolski
Dana Bielopolski
BRBenaya Rozen-Zvi
Benaya Rozen-Zvi
Selecting the optimal first-line therapy for type 2 diabetes is essential for achieving glycemic control and providing cardio-renal protection, though the combined benefits of metformin with SGLT2 inhibitors, remain uncertain. This retrospective cohort study analyzed data from Clalit Health Services (2016–2021), to compare outcome in adults with type 2 diabetes treated with SGLT2 inhibitors alone versus in combination with metformin. Propensity score matching was applied to balance baseline characteristics between groups. Primary outcomes were a composite kidney outcome (40% decline in eGFR, or progression to ESRD), and all-cause mortality. Safety outcomes included hospitalizations, acute kidney injury and metabolic acidosis. The study included 45,545 patients, with 6774 patients in each group following propensity score matching. The median follow-up time was 1166 days. Combination therapy with metformin and SGLT2 inhibitors was associated with significantly reduced risk of all-cause mortality (aHR 0.74, 95% CI 0.64–0.84), and composite kidney outcomes (aHR 0.65 95% CI 0.48–0.87) even after accounting for mortality as a competing risk (aHR 0.67; 95% CI 0.5–0.9). Furthermore, combination therapy was associated with reduced risks of hospitalization (aHR 0.93 95% CI 0.87–0.99), severe acute kidney injury events (aHR 0.72 95% CI 0.54–0.96) and metabolic acidosis events (aHR 0.58 95% CI 0.4–0.83), compared with SGLT2 inhibitors alone. Patients receiving combination therapy with metformin and SGLT2 inhibitors showed significantly reduced risks of kidney disease progression and mortality compared to those treated with SGLT2 inhibitors alone. These findings support the use of metformin with SGLT2 inhibitors as a first-line treatment strategy for type 2 diabetes irrespective of glycemic control or cardio-renal risk factors.

27 July 2022 in Nephron
Verified
Journal Article
Open access
PDF file
TATimna Agur
Timna Agur
BZBoris Zingerman
Boris Zingerman
NBNaomi Ben-Dor
Naomi Ben-Dor
WAWeaam Alkeesh
Weaam Alkeesh
TSTali Steinmetz
Tali Steinmetz
MHMichal Herman-Edelstein
Michal Herman-Edelstein
Background: Hemodialysis patients are at high risk for severe COVID-19 disease. Despite a high early seropositivity rate, dialysis patients mount a dampened immune response following two doses of an mRNA vaccine. This study aimed to evaluate the serologic response to a booster dose of BNT162b2 vaccine, 6 months after the second dose, among hemodialysis patients. Methods: This prospective study included 80 hemodialysis patients and 56 healthcare workers serving as controls. Serologic samples were evaluated before and ∼3 weeks after the third vaccine dose. The primary outcomes were the seropositivity rate and the log-transformed anti-SARS-COV-2 S1 (RBD) IgG as a continuous variable after the third dose. Secondary outcomes were the proportion of participants with “high response,” defined as antibody levels >1,000 AU/mL, and “robust response,” defined as antibody levels >4,160 AU/mL, according to prespecified cutoff values associated with neutralizing antibodies. Univariate and multivariate analyses were conducted to identify predictors of antibody response. Results: Among 80 hemodialysis patients, seropositivity rates improved from 78% (62/80) before the third dose, up to 96% (77/80) after the booster dose. The S1-RBD log-transformed antibody level increased significantly following the third dose from 2.15 ± 0.75 to 3.99 ± 0.83 compared with 2.65 ± 0.4 to 4.31 ± 0.42 in the control group. Among the hemodialysis patients, 88% (70/80) became “high responders” (>1,000 AU/mL), and of these, 79% (63/80) mounted a “robust response” (>4,160 AU/mL). Baseline antibody level, dialysis therapy, and hypoalbuminemia were independent predictors of impaired antibody response. Conclusions: A third dose of BNT162b2 COVID-19 vaccine, 6 months after the standard two-dose vaccination regimen, substantially improved humoral response in hemodialysis patients.

17 June 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
MHMichal Herman-Edelstein
Michal Herman-Edelstein
NBNaomi Ben-Dor
Naomi Ben-Dor
TATimna Agur
Timna Agur
TGTali Guetta
Tali Guetta
ARAnnat Raiter
Annat Raiter
BZBoris Zingerman
Boris Zingerman
Background: The emergence of new SARS-CoV-2 variants, which evade immunity, has raised the urgent need for multiple vaccine booster doses for vulnerable populations. In this study, we aimed to estimate the BNT162b2 booster effectiveness against the spread of coronavirus variants in a hemodialysis population. Methods: We compared humoral and cell-mediated immunity in 100 dialysis patients and 66 age-matched volunteers, before and 2–3 weeks following the first booster vaccine dose. Participants were assessed for anti-spike (RBD) antibody titer, neutralizing antibodies against B.1.617.2 (Delta) and B.1.1.529 (Omicron) variants, spike-specific T-cell responses by FACS and infection outbreak after the first and second booster. Results: Anti-spike antibody titer was significantly increased following the booster, with reduced humoral and cellular response in the dialysis patients. Neutralizing antibody levels increased significantly after the booster dose, with an inferior effect (≤2 fold) against Omicron compared with the Delta variant. Furthermore, CD4+ and CD8+ T-cell activation by Delta spike protein was preserved in 70% of PBMCs from the dialysis patients. A second booster dose tended to reduce breakthrough infections in the dialysis patients. Conclusions: Until the release of an updated vaccine, BNT162b2 booster doses will improve the humoral and cell-mediated immunity against variants. These findings support the importance of repetitive booster doses for hemodialysis patients.

20 December 2022 in Clinical Transplantation
Verified
Journal Article
Open access
TATimna Agur
Timna Agur
RRRuth Rahamimov
Ruth Rahamimov
BZBoris Zingerman
Boris Zingerman
DBDana Bielopolski
Dana Bielopolski
SLShelly Lichtenberg
Shelly Lichtenberg
BRBenaya Rozen‐Zvi
Benaya Rozen‐Zvi
Background: Accumulating data indicate that sub‐therapeutic levels of tacrolimus are associated with long‐term kidney graft loss. However, elevated doses increase the risk of infection and drug toxicity, which also threaten graft and patient longevity. We sought to determine the minimal tacrolimus level required to maintain graft survival.Methods: We conducted a single‐center historical cohort study. The first‐year post‐transplant exposure time was calculated for each of the five tacrolimus trough level intervals. This measure was adjusted to the exposure time below a given interval level, allowing us to define the threshold for the optimal tacrolimus level as the upper limit of the interval. We then determined the association between the adjusted exposure time at each tacrolimus level interval and our primary outcome, death‐censored graft loss.Results: One thousand four hundred and seventeen patients with a median follow‐up of 5.3 years were included in the final cohort. The tacrolimus level interval of 5–6 ng/ml was the highest interval, which demonstrated a statistically significant association between adjusted exposure time and increased risk of graft loss (HR 1.58, per log days, p = .002). Cumulative exposure time above 14 days with a tacrolimus level below 6 ng/ml was associated with an increased rate of graft loss in most studied subgroups, except for recipients with pre transplant diabetes.Conclusions: Maintaining tacrolimus levels above 6 ng/ml during the first‐year post‐transplant might improve kidney graft survival.